doxazosin has been researched along with Cardiovascular Diseases in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 16 (84.21) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coifman, RR; Coppi, AC; Davis, BR; Dhruva, SS; Furberg, CD; Huang, C; Krumholz, HM; Li, SX; Lin, H; Pressel, SL; Spatz, ES; Warner, F; Xu, X | 1 |
| Hoogenberg, K; van der Tuin, J | 1 |
| Janssen, CA | 1 |
| Barzilay, JI; Basile, JN; Bettencourt, J; Black, H; Ciocon, JO; Davis, BR; Ellsworth, A; Force, RW; Goff, DC; Habib, G; Margolis, KL; Wiegmann, T | 1 |
| Ebina, T | 1 |
| Arnett, DK; Black, H; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Miller, MB | 1 |
| O'Leary, MP | 1 |
| Yusuf, S | 1 |
| Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI | 1 |
| Fulton, B; Sorkin, EM; Wagstaff, AJ | 1 |
| Lasagna, L | 1 |
| Ukhal', GM; Ukhal', MI | 1 |
| Koval, PG; McDiarmid, T | 1 |
| Hooper, PL | 2 |
| Furberg, CD | 1 |
3 review(s) available for doxazosin and Cardiovascular Diseases
| Article | Year |
|---|---|
[Alpha blocker for protection against hypertensive target-organ damage].
Topics: Adrenergic alpha-Antagonists; Binding, Competitive; Blood Pressure; Cardiovascular Diseases; Circadian Rhythm; Clinical Trials as Topic; Contraindications; Doxazosin; Humans; Hypertension; Lipid Metabolism; Norepinephrine; Practice Guidelines as Topic; Receptors, Adrenergic, alpha-1 | 2004 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
Topics: Carbohydrate Metabolism; Cardiovascular Diseases; Dosage Forms; Doxazosin; Drug Evaluation; Heart Ventricles; Hemodynamics; Humans; Hypertension; Lipid Metabolism; Male; Prostatic Hyperplasia | 1995 |
5 trial(s) available for doxazosin and Cardiovascular Diseases
| Article | Year |
|---|---|
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Doxazosin; Drug Monitoring; Female; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Lisinopril; Male; Middle Aged; Treatment Outcome | 2017 |
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Doxazosin; Female; Humans; Hyperglycemia; Hypertension; Male; Risk Factors; Treatment Outcome | 2004 |
Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Double-Blind Method; Doxazosin; Female; Follow-Up Studies; Genotype; Humans; Lisinopril; Male; Middle Aged; Peptidyl-Dipeptidase A; Pharmacogenetics; Polymorphism, Genetic; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2005 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Diuretics; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Lisinopril; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk; Survival Analysis | 2000 |
[The effect of symptomatic therapy with the alpha 1-adrenoblocker Cardura in patients with benign prostatic hyperplasia on the course of cardiovascular diseases].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Cardiovascular Diseases; Disease Progression; Doxazosin; Hemodynamics; Humans; Male; Middle Aged; Palliative Care; Prostatic Hyperplasia; Time Factors; Urodynamics | 1999 |
11 other study(ies) available for doxazosin and Cardiovascular Diseases
| Article | Year |
|---|---|
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Topics: Adrenergic alpha-Antagonists; Advertising; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Doxazosin; Humans; Hypertension; Netherlands; Practice Guidelines as Topic; Treatment Outcome | 2002 |
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Topics: Adrenergic alpha-Antagonists; Advertising; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Doxazosin; Humans; Hypertension; Netherlands; Practice Guidelines as Topic; Treatment Outcome | 2003 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Doxazosin; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Sodium Chloride Symporter Inhibitors; Treatment Outcome | 2005 |
Preventing vascular events due to elevated blood pressure.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Comorbidity; Doxazosin; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk Factors; Stroke | 2006 |
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; Diuretics; Doxazosin; Female; Genotype; Humans; Hypertension; Lisinopril; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide | 2008 |
Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Diuretics; Doxazosin; Humans; Hypertension; Randomized Controlled Trials as Topic | 2000 |
Diuretics vs. alpha blockers.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diuretics; Doxazosin; Heart Failure; Humans; Hypertension; Myocardial Infarction | 2000 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Random Allocation; Reproducibility of Results; Research Design; Risk Factors; Stroke | 2000 |
Reduced heat shock proteins--a mechanism to explain higher cardiovascular events associated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Cardiovascular Diseases; Doxazosin; Heat-Shock Proteins; Humans | 2001 |
Reduced heat shock proteins: a mechanism to explain higher cardiovascular events associated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Cardiovascular Diseases; Doxazosin; Heat-Shock Proteins; Humans | 2001 |
Doxazosin, an inferior antihypertensive agent?
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Controlled Clinical Trials as Topic; Diuretics; Doxazosin; Female; Follow-Up Studies; Humans; Hypertension; Male; Practice Guidelines as Topic; Withholding Treatment | 2002 |